Is PI-RADS 4 Always Cancer? What This Score Means

A PI-RADS 4 score on a prostate MRI is not a cancer diagnosis. It signals that a clinically significant cancer is “likely” present, but across large pooled analyses, roughly half to two-thirds of PI-RADS 4 lesions turn out to contain clinically significant prostate cancer. That means a substantial minority of men with this score will have benign tissue or low-grade disease that may not need aggressive treatment. The gap between “likely” and “definite” is where a lot of anxiety, and a lot of important clinical decision-making, lives.

What the Detection Rates Actually Look Like

The PI-RADS system assigns scores from 1 (clinically significant cancer is highly unlikely) to 5 (highly likely). PI-RADS 4 sits in the “likely” tier, and the cancer detection rates reflect that probabilistic language. A systematic review and meta-analysis pooling data from multiple studies found that on a per-lesion basis, about 52% of PI-RADS 4 lesions contained cancer, while on a per-patient basis the figure was about 59%.¹ For context, PI-RADS 5 lesions in the same analysis showed detection rates around 89% at the lesion level and 85% at the patient level, while PI-RADS 3 lesions hovered around 20% and 16%.

Individual studies report somewhat different numbers depending on their patient mix and biopsy methods. One retrospective study using transperineal biopsy found clinically significant cancer in about 60% of PI-RADS 4 lesions.² Another study using in-bore MRI-guided biopsy reported that about 72% of patients with PI-RADS 4 lesions had some form of prostate cancer, though only about 54% had clinically significant disease.³ A study of men who went on to radical prostatectomy found clinically significant cancer in about 67% of those with PI-RADS 4 lesions.⁴

The spread across studies reflects real differences in how patients are selected, how biopsies are performed, and who reads the MRI. But the core message stays consistent: PI-RADS 4 means cancer is found more often than not, yet roughly a third to nearly half of men with this score will not have clinically significant disease.

What Creates a False Positive at PI-RADS 4

If cancer explains only about half to two-thirds of PI-RADS 4 lesions, what explains the rest? Several benign conditions can mimic prostate cancer on MRI, particularly on diffusion-weighted imaging, which is a key sequence for scoring lesions in the outer part of the gland (the peripheral zone).⁵

Prostate inflammation (prostatitis) is one of the most common culprits. A study examining biopsy results found that high-grade prostatic inflammation significantly raised the false-positive rate for PI-RADS 4 and 5 lesions. Among men with highly aggressive inflammation, nearly 60% of PI-RADS 4/5 findings turned out to be false positives for any cancer.⁶ Inflammation causes tissue swelling and restricts water movement in cells, producing MRI signals that look very similar to cancer.

Benign prostatic hyperplasia (BPH) is another major source of confusion, especially for lesions in the transition zone, the inner part of the gland where BPH originates. One study analyzing false-positive PI-RADS 4 results found that transition zone location and the presence of multiple lesions were strong indicators that BPH, not cancer, was responsible. The researchers concluded that current MRI technology still cannot reliably tell apart atypical BPH nodules from malignant tumors when both sit in the transition zone and earn a PI-RADS 4 score.⁷ A separate single-center analysis confirmed that benign findings are common among PI-RADS 4 lesions and that most of those benign lesions do not even show the kind of cellular overcrowding you would expect from a typical hyperplastic nodule.⁸

A detailed review of PI-RADS 4 and 5 lesions that turned out negative on biopsy found that among 90 patients eventually cleared of cancer, about 44% had their PI-RADS score considered an overestimation on second review. Many of those were transition zone lesions with clear boundaries that mimicked higher-risk findings. Rarer mimics included granulomatous inflammation and even prostate tuberculosis. Roughly a third of the negative cases fell into an ambiguous zone where the imaging features sat right on the border between PI-RADS 3 and 4.⁹

Why Lesion Size Changes the Odds

Not all PI-RADS 4 lesions carry the same level of risk. Lesion size is one of the strongest modifiers. The study examining in-bore biopsies found that when PI-RADS 4 lesions were smaller than 5 mm, about 43% harbored clinically significant cancer. For lesions between 5 and 10 mm, that figure rose to about 51%, and for lesions larger than 10 mm, it climbed to roughly 65%.³ The transperineal biopsy study identified an optimal size cutoff of about 8.5 mm: lesions above that threshold carried roughly 2.3 times the risk of clinically significant cancer compared to smaller ones.²

This means a small PI-RADS 4 lesion is genuinely less worrisome than a large one, even though both receive the same score. Some researchers have proposed formally subcategorizing PI-RADS 4 into higher- and lower-suspicion tiers based on imaging characteristics like ADC values (a measure of water diffusion in tissue). One study that attempted this split found clinically significant cancer in about 61% of “PI-RADS 4+” lesions but only 17% of “PI-RADS 4−” lesions.¹⁰ That is a huge range within a single scoring category, and it underscores why PI-RADS 4 should be treated as a starting point for risk assessment rather than a final verdict.

How PSA Density Refines the Picture

PSA density (your PSA level divided by the volume of your prostate on imaging) adds another layer of information on top of the PI-RADS score. A study examining how PSA density interacts with PI-RADS found that among men with PI-RADS 4 lesions and a low PSA density (below 0.1), only about 5% were found to have clinically significant cancer. When PSA density was high, that jumped to about 22%.¹¹ The researchers described the effect as roughly equivalent to bumping the PI-RADS score up or down by one point. A PI-RADS 4 with high PSA density behaves more like a PI-RADS 5 in terms of cancer risk, while a PI-RADS 4 with low PSA density behaves more like a PI-RADS 3.

Combining PSA density with PSA velocity (how fast your PSA is rising over time) may help reduce unnecessary biopsies. One study looking at PI-RADS 3 and 4 lesions found that this combination reduced unnecessary biopsies by about 68%, though it came at the cost of missing about a third of clinically significant cancers.¹² That trade-off is worth discussing with your urologist, especially if your personal circumstances make the risks of biopsy weigh heavily.

Biopsy Approach Matters More Than You Might Think

For PI-RADS 4 lesions specifically, the way the biopsy is performed can meaningfully change whether cancer is found. The two main routes are transperineal (through the skin between the scrotum and rectum) and transrectal (through the rectal wall). Both approaches detect similar rates of clinically significant cancer overall, but PI-RADS 4 is exactly where the differences emerge.

A comparison of transperineal and transrectal fusion biopsies found similar clinically significant cancer detection for PI-RADS 3 and PI-RADS 5 lesions, but the transperineal approach showed a statistically significant advantage for PI-RADS 4 lesions specifically.¹³ A lesion-level analysis confirmed this pattern: transperineal targeted biopsy was an independent predictor of detecting clinically significant cancer after adjusting for age, PSA, prostate volume, and other factors.¹⁴

Why would the route matter? The transperineal approach tends to yield longer biopsy cores with more tissue, which makes it easier to sample a suspicious lesion fully.¹⁵ For a lesion that is borderline in size or sits in a tricky location, that extra tissue can make the difference between catching cancer and missing it. Targeted biopsy in general also outperforms systematic (non-targeted) biopsy for PI-RADS 4 lesions when it comes to both detecting clinically significant cancer and avoiding the detection of low-grade disease that might not need treatment.¹⁶

The Radiologist Reading Your MRI Makes a Difference

PI-RADS scores are assigned by radiologists, and the experience of the person reading the scan affects both the score itself and its accuracy. A study comparing five radiologists with different levels of experience found that the least experienced reader had a sensitivity of 78% and accuracy of about 87% for detecting clinically significant cancer in the transition zone, while the most experienced reader reached 88% sensitivity and 92% accuracy.¹⁷ That gap of ten percentage points in sensitivity is real, and it means the same prostate could receive a PI-RADS 3 from one radiologist and a PI-RADS 4 from another.

Another study involving six radiologists found that the updated PI-RADS version (2.1) improved agreement between readers for transition zone lesions, but the diagnostic accuracy in the transition zone remained modest overall, with an average area under the curve of about 0.69 regardless of which version was used.¹⁸ In the peripheral zone, experienced readers performed better with the newer version. The practical implication is that if you receive a PI-RADS 4 score and you are at a center without specialized prostate MRI expertise, a second read by a dedicated uroradiologist can sometimes change the score and the clinical plan.

What Happens When a PI-RADS 4 Biopsy Comes Back Negative

A negative biopsy after a PI-RADS 4 or 5 finding does not necessarily close the book. Persistent high-scoring lesions on follow-up MRI carry a meaningful risk of missed cancer due to factors like prostate deformation during the biopsy, patient movement, or misalignment between the MRI images and the ultrasound used to guide the needle.¹⁹ Smaller lesion size, lower PSA density, and the absence of a suspicious digital rectal exam were all associated with a higher probability of getting a false-negative targeted biopsy result.²⁰

In practice, urologists typically recommend a follow-up MRI within a year for men with PI-RADS 4/5 lesions and negative biopsies. If the lesion persists or grows, a repeat biopsy is usually advised. Research into whole-gland MRI-based radiomics (computer analysis of imaging features) is exploring whether it can help predict which of these men will eventually be diagnosed with cancer, though this work is still in early stages.²¹

Emerging Tools That May Sharpen the Diagnosis

Two technologies are gaining traction for resolving the ambiguity around PI-RADS 4 lesions. The first is PSMA PET/CT, a molecular imaging scan that detects a protein (PSMA) found at high levels on prostate cancer cells. In men with PI-RADS 4/5 lesions and a prior negative biopsy, PSMA PET/CT can help clarify whether a lesion is truly suspicious.²² Combining PSMA PET with MRI produces even better diagnostic accuracy. One study found that when a PI-RADS 4/5 lesion also showed a PSMA uptake value above a certain threshold, the combination predicted malignancy with 83% sensitivity and 100% specificity.²³

The second is artificial intelligence. Multi-center testing of a commercially available AI algorithm for PI-RADS scoring found that its sensitivity for detecting clinically significant cancer was comparable to radiologists (about 91% vs. 92% at the patient level when using PI-RADS 4 or higher as the cutoff), though radiologists still had an edge in specificity, meaning they were somewhat better at correctly identifying benign lesions.²⁴ Machine learning approaches are also being explored specifically for reducing false positives by classifying lesion tissue as benign or malignant from MRI data.²⁵ Neither technology has replaced the standard MRI-plus-biopsy pathway, but both represent promising additions, especially for the gray zone that PI-RADS 4 occupies.

The Cost-Effectiveness Angle

For men already diagnosed with low-risk prostate cancer who are on active surveillance (monitoring rather than immediate treatment), the question shifts from “do I have cancer” to “how often should I be checked, and what findings should trigger a biopsy?” A cost-effectiveness analysis found that performing annual MRI and reserving biopsy for lesions scoring PI-RADS 4 or higher was the most cost-effective surveillance strategy for men under 70 with low-risk disease.²⁶ Using a PI-RADS 4 threshold rather than biopsying at PI-RADS 3 reduced the number of unnecessary biopsies while still catching disease progression at a cost society considers reasonable.

In the diagnostic setting, strategies that incorporate MRI-targeted biopsy are generally cost-effective compared to older systematic biopsy approaches, though the exact value depends on local healthcare costs and the willingness-to-pay threshold used.²⁷ The broader point is that the PI-RADS 4 threshold is not arbitrary; it reflects a balance point where the likelihood of finding meaningful disease justifies the costs and risks of proceeding to biopsy.

Grading After Diagnosis and the Upgrading Problem

Even when a PI-RADS 4 lesion does contain cancer, the initial biopsy grade does not always match what is found if the prostate is eventually removed surgically. The study of men who underwent radical prostatectomy found that about 24% of those with PI-RADS 4 lesions had their cancer upgraded to a higher grade group on final pathology.⁴ Upgrading means the cancer turned out to be more aggressive than the biopsy suggested. Interestingly, the upgrading rate was not highest in the PI-RADS 4 group; PI-RADS 5 lesions actually had the highest rate at about 38%, suggesting a non-linear relationship between imaging suspicion and pathological surprise.

For you as a patient, this means a PI-RADS 4 lesion that yields a low-grade cancer on biopsy still warrants careful discussion about monitoring versus treatment. The roughly one-in-four chance of upgrading is not a reason to panic, but it is a reason to stay in close follow-up if active surveillance is chosen. It also reinforces why biopsy technique and sampling thoroughness matter so much: a well-targeted, high-quality biopsy gives the pathologist more tissue to work with and reduces the odds of an unwelcome surprise later.